'Rapid Learning health care in oncology' - An approach towards decision support systems enabling customised radiotherapy

Radiotherapy and Oncology

Volumn 109, Issue 1, 2013, Pages 159-164

  Lambin, Philippe ^a   Roelofs, Erik ^a   Reymen, Bart ^a   Velazquez, Emmanuel Rios ^a   Buijsen, Jeroen ^a   Zegers, Catharina M L ^a   Carvalho, Sara ^a   Leijenaar, Ralph T H ^a   Nalbantov, Georgi ^a   Oberije, Cary ^a   Scott Marshall, M ^a   Hoebers, Frank ^a   Troost, Esther G C ^a   Van Stiphout, Ruud G P M ^a   Van Elmpt, Wouter ^a   Van Der Weijden, Trudy ^a   Boersma, Liesbeth ^a   Valentini, Vincenzo ^b   Dekker, Andre ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cancer; Decision support system (dss); Radiotherapy; Rapid learning; Tailored radiation treatment

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MACHINE LEARNING; MEDICAL RECORD; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

CANCER; DECISION SUPPORT SYSTEM (DSS); RADIOTHERAPY; RAPID LEARNING; TAILORED RADIATION TREATMENT;

DECISION SUPPORT SYSTEMS, CLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; LEARNING; NEOPLASMS;

EID: 84888072190     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.07.007     Document Type: Article

References (43)

1. P. Lambin, S.F. Petit, H.J. Aerts, W.J. van Elmpt, C.J. Oberije, and M.H. Starmans From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer Radiother Oncol 2010 2009 145 152
2. D.C. Koboldt, R.S. Fulton, and M.D. McLellan Comprehensive molecular portraits of human breast tumours Nature 490 7418 2012 61 70
3. R. Seigneuric, M.H. Starmans, G. Fung, B. Krishnapuram, D.S. Nuyten, and A. van Erk Impact of supervised gene signatures of early hypoxia on patient survival Radiother Oncol 83 2007 374 382
4. M.H. Starmans, K.C. Chu, S. Haider, F. Nguyen, R. Seigneuric, and M.G. Magagnin The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer Radiother Oncol 102 2012 436 443
5. M.H. Starmans, G. Fung, H. Steck, B.G. Wouters, and P. Lambin A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures PLoS ONE 6 2011 e28320
6. M.H. Starmans, N.G. Lieuwes, P.N. Span, S. Haider, L. Dubois, and F. Nguyen Independent and functional validation of a multi-tumour-type proliferation signature Br. J. Cancer 107 2012 508 515
7. M.H. Starmans, D. Zips, B.G. Wouters, M. Baumann, and P. Lambin The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response Radiother Oncol 92 2009 417 422
8. A.M. Voets, C. Oberije, R.B. Struijk, B. Reymen, K. De Ruyck, and H. Thierens No association between TGF-beta1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients Radiother Oncol 105 2012 296 298
9. B. Movsas, J. Moughan, J. Owen, L.R. Coia, M.J. Zelefsky, and G. Hanks Who enrolls onto clinical oncology trials? A radiation patterns of care study analysis Int J Radiat Oncol Biol Phys 68 2007 1145 1150
10. M.M. Grand, and P.C. O'Brien Obstacles to participation in randomised cancer clinical trials: a systematic review of the literature J Med Imag Radiat Oncol 56 2012 31 39
11. V.H. Murthy, H.M. Krumholz, and C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
12. H. Bastian, P. Glasziou, and I. Chalmers Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 7 2010 e1000326
13. A.P. Abernethy, L.M. Etheredge, P.A. Ganz, P. Wallace, R.R. German, and C. Neti Rapid-learning system for cancer care J Clin Oncol 28 2010 4268 4274
14. C. Dehing-Oberije, S. Yu, D. De Ruysscher, S. Meersschout, K. Van Beek, and Y. Lievens Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 74 2009 355 362
15. A.G. Egelmeer, E.R. Velazquez, J.M. de Jong, C. Oberije, Y. Geussens, and S. Nuyts Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients Radiother Oncol 100 2011 108 115
16. M.F. Jimenez, A. van Baardwijk, H.J. Aerts, D. De Ruysscher, N.M. Novoa, and G. Varela Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis Radiother Oncol 97 2010 413 417
17. E. Roelofs, M. Engelsman, C. Rasch, L. Persoon, S. Qamhiyeh, and D. de Ruysscher Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer J Oncol 7 2012 165 176
18. P. Lambin, E. Rios-Velazquez, R. Leijenaar, S. Carvalho, R.G. van Stiphout, and P. Granton Radiomics: extracting more information from medical images using advanced feature analysis Eur J Cancer 48 2012 441 446
19. E. Roelofs, L. Persoon, S. Nijsten, W. Wiessler, A. Dekker, and P. Lambin Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial Radiother Oncol 2013 doi:pii: S0167-8140(12)00444-6
20. W. van Elmpt, S. Nijsten, B. Mijnheer, A. Dekker, and P. Lambin The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based on EPID dosimetry and Monte Carlo dose calculations Radiother Oncol 86 2008 86 92
21. E.W. Steyerberg, A.J. Vickers, N.R. Cook, T. Gerds, M. Gonen, and N. Obuchowski Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 21 2010 128 138
22. V. Valentini, R.G. van Stiphout, G. Lammering, M.A. Gambacorta, M.C. Barba, and M. Bebenek Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials J Clin Oncol 29 2011 3163 3172
23. D. De Ruysscher, C. Dehing, S. Yu, R. Wanders, M. Ollers, and A.M. Dingemans Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer Radiother Oncol 91 2009 353 359
24. D. De Ruysscher, A. Houben, H.J. Aerts, C. Dehing, R. Wanders, and M. Ollers Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent radiation-induced lung toxicity (RILT): a prospective pilot study Radiother Oncol 91 2009 415 420
25. C. Dehing-Oberije, D. De Ruysscher, A. van Baardwijk, S. Yu, B. Rao, and P. Lambin The importance of patient characteristics for the prediction of radiation-induced lung toxicity Radiother Oncol 91 2009 421 426
26. D. Stacey, C.L. Bennett, M.J. Barry, N.F. Col, K.B. Eden, and M. Holmes-Rovner Decision aids for people facing health treatment or screening decisions Cochrane Database Syst Rev 2011 CD001431
27. S.M. Bentzen, W. Dorr, R. Gahbauer, R.W. Howell, M.C. Joiner, and B. Jones Bioeffect modeling and equieffective dose concepts in radiation oncology-terminology, quantities and units Radiother Oncol 105 2012 266 268
28. A.A. De Leeuw, J.B. Van de Kamer, M.A. Moerland, M.E. Philippens, and I.M. Jurgenliemk-Schulz The effect of alternative biological modelling parameters (alpha/beta and half time of repair T(1/2)) on reported EQD2 values in the treatment of advanced cervical cancer Radiother Oncol 101 2011 337 342
29. R. Guo, Y. Sun, and X.L. Yu Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol 104 2012 294 299
30. P. Lambin, R.G. van Stiphout, M.H. Starmans, E. Rios-Velazquez, G. Nalbantov, and H.J. Aerts Predicting outcomes in radiation oncology - multifactorial decision support systems Nature Rev Clin Oncol 10 2013 27 40
31. C. Dehing-Oberije, D. De Ruysscher, S. Petit, J. Van Meerbeeck, K. Vandecasteele, and W. De Neve Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients Radiother Oncol 97 2010 455 461
32. C. Dehing-Oberije, H. Aerts, S. Yu, D. De Ruysscher, P. Menheere, and M. Hilvo Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325) Int J Radiat Oncol Biol Phys 81 2011 360 368
33. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
34. A. Trotti, A.D. Colevas, A. Setser, V. Rusch, D. Jaques, and V. Budach CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
35. J.P. Grutters, A.G. Kessels, M. Pijls-Johannesma, D. De Ruysscher, M.A. Joore, and P. Lambin Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis Radiother Oncol 95 2010 32 40
36. A. Peeters, J.P. Grutters, M. Pijls-Johannesma, S. Reimoser, D. De Ruysscher, and J.L. Severens How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons Radiother Oncol 95 2010 45 53
37. H.J. Aerts, J. Bussink, W.J. Oyen, W. van Elmpt, A.M. Folgering, and D. Emans Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation Lung Cancer 75 2012 73 76
38. J. van Loon, M.H. Janssen, M. Ollers, H.J. Aerts, L. Dubois, and M. Hochstenbag PET imaging of hypoxia using [18F]HX4: a phase I trial Eur J Nucl Med Mol Imag 37 2010 1663 1668
39. L.S. Mortensen, J. Johansen, J. Kallehauge, H. Primdahl, M. Busk, and P. Lassen FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
40. D. Zips, K. Zophel, N. Abolmaali, R. Perrin, A. Abramyuk, and R. Haase Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head- and-neck cancer Radiother Oncol 105 2012 21 28
41. J.A. Langendijk, P. Lambin, D. De Ruysscher, J. Widder, M. Bos, and M. Verheij Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach Radiother Oncol 2013
42. A.M. Stiggelbout, T. Van der Weijden, M.P. De Wit, D. Frosch, F. Legare, and V.M. Montori Shared decision making: really putting patients at the centre of healthcare BMJ 344 2012 e256
43. J.O. Deasy, S.M. Bentzen, A. Jackson, R.K. Ten Haken, E.D. Yorke, and L.S. Constine Improving normal tissue complication probability models: the need to adopt a "data-pooling" culture Int J Radiat Oncol Biol Phys. 76 3 Suppl 2010 S151 S154